<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325921</url>
  </required_header>
  <id_info>
    <org_study_id>NL49616.091.14</org_study_id>
    <nct_id>NCT02325921</nct_id>
  </id_info>
  <brief_title>MRI in Renal Tumors</brief_title>
  <official_title>Advanced MRI in Renal Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnostic imaging for renal masses of unknown nature using conventional imaging modalities
      such as 3 phase contrast-enhanced computed tomography (CT) is not always conclusive. After
      (partial) nephrectomy, 10-20 % of the resected tumors show benign histology which could not
      be identified on diagnostic imaging. With improved imaging techniques available, leading to
      improvements in characterisation of renal tumors, the number of unnecessary resections may be
      reduced. The objective of this study is to evaluate the diagnostic performance of diffusion
      weighted magnetic resonance imaging (DW-MRl) in assessing the nature of renal masses,
      including the use of diffusion tensor imaging (DTI).Therefore patients &gt;18 years of age
      scheduled for undergoing (partial) tumor nephrectomy will undergo one additional MRI
      examination.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Week</target_duration>
  <primary_outcome>
    <measure>Discriminating malignant from benign lesions using Apparent Diffusion Coefficient (ADC) values, a metric obtained by diffusion weighted MRI.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To distinguish histological subtypes of renal tumors using Apparent Diffusion Coefficient (ADC), mean diffusivity and Fractional Anisotropy (FA) values, metrics obtained by Diffusion Tensor Imaging (DTI).</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>(Partial) nephrectomy</arm_group_label>
    <description>Patients &gt;18 years of age scheduled for undergoing (partial) tumor nephrectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>One MRI examination, diagnostic scanning protocol as used for renal tumours with additional diffusion weighted sequences (including diffusion tensor imaging), but without contrast enhancement.</description>
    <arm_group_label>(Partial) nephrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients &gt;18 years of age scheduled for undergoing (partial) tumor nephrectomy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned to undergo (partial) tumor nephrectomy of at least one untreated tumor of one
             kidney;

          -  Signed Institutional Review Board (IRB) approved informed consent form.

        Exclusion Criteria:

          -  Relative contra indications for MRI (metal device/foreign bodies, claustrophobia);

          -  Active renal or perirenal infection;

          -  Minor and/or incapacitated adult.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jurgen J. Futterer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2014</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Diffusion Weighted MRI</keyword>
  <keyword>Diffusion Tensor Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

